Search clinical trials for: Immunological Mechanisms

Total 100360 results

Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CBM588 in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Anlotinib And Chemotherapy (SOX) In Neoadjuvant Therapy For Locally Advanced Adenocarcinoma Of Esophagogastric Junction

Immunotherapy Gastroesophageal Junction

China
Chinese PLA General Hospital

Not yet recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR

Triple-Negative Breast Cancer
Centre Leon Berard
Groupe Français de Pneumo-Cancérologie

Not yet recruiting

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC)

Large Cell Neuroendocrine Carcinoma of the Lung

France
The Methodist Hospital Research Institute

Recruiting

IL-2 Plus Abatacept in FTD

Frontotemporal Degeneration

United States
Narendranath Epperla
Eli Lilly and Company

Not yet recruiting

Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
Fudan University
Shanghai Zhongshan Hospital; RenJi Hospital; First Hospital of China Medical... and other collaborators

Not yet recruiting

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Rectal Cancer | RECTAL NEOPLASMS
Genmab
BioNTech SE

Recruiting

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Malignant Solid Tumor

Spain
University Hospital, Essen
Bristol-Myers Squibb; Advanced Accelerator Applications

Not yet recruiting

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NEPI)

Very High Risk Prostate Carcinoma

Germany
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma | Radiotherapy | Pembrolizumab | Tumor Thrombosis

China
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
The First Affiliated Hospital of Xiamen University

Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (SEGNO)

Oligometastatic Prostate Cancer | Locally Advanced Prostate Cancer

China
Duke University
Regeneron Pharmaceuticals

Not yet recruiting

TOP 2301: Neoadjuvant Chemo for NSCLC

Non Small Cell Lung Cancer
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Amsterdam UMC, location VUmc
Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital

Not yet recruiting

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) (PREOPANC-5)

Borderline Resectable Pancreatic Cancer
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc.

Recruiting

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Vall d'Hebron Institute of Oncology

Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)

Ovarian Cancer

Spain
University Health Network, Toronto

Not yet recruiting

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Melanoma (Skin)

Canada
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (NeoSCLC-001)

Limited-stage Small-cell Lung Cancer
Francesco De Cobelli
A.O. Ospedale Papa Giovanni XXIII; Cardarelli Hospital; AOU Pisana, Pisa, Italy

Not yet recruiting

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE)

Intrahepatic Cholangiocarcinoma

Italy
Yehua Shen

Not yet recruiting

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

HCC - Hepatocellular Carcinoma
Saint Petersburg State University, Russia

Recruiting

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer

Russian Federation
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Gustave Roussy, Cancer Campus, Grand Paris
Medical University of Vienna; University Hospital, Essen; Fondazione IRCCS Istituto... and other collaborators

Recruiting

CARE1 Pragmatic Clinical Trial (CARE1)

Metastatic Kidney Carcinoma | Metastatic Kidney Cancer

France
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Lantheus Medical Imaging

Not yet recruiting

PSMA Therapy and Immunotherapy in Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma
Zhongnan Hospital

Not yet recruiting

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Endometrial Neoplasms

China
7 Hills Pharma, LLC

Not yet recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China

Search clinical trials for: Immunological Mechanisms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations